$WLKP

Westlake Chemical Partners LP (WLKP): Results of Operations and Financial Condition

Westlake Chemical Partners LP (WLKP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991_20260630earningsrele.htm EX-99.1 Document EXHIBIT 99.1 WESTLAKE CHEMICAL PARTNERS LP Contact—(713) 585-2900 Investors—Jonathan Baksht Media—L. Benjamin Ederington Westlake Chemical Partners LP Announces Second Quarter 2026 Results • Declared quarterly distribution

Original reporting
Published Aug 4, 2026, 11:27 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$WLKP
Bullish
medium confidence
Mentioned
$WLKP
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$WLKPBullishMed
01

Why it matters

Traders can update models for distributable cash flow, coverage, and near-term liquidity risk based on the new quarter’s operating cash flow and the credit agreement maturity extension.

02

Market read

Fresh quarterly earnings and distribution details, plus a credit facility maturity extension, are directly relevant to income and credit-risk positioning in WLKP.

03

What to watch

The release highlights lower maintenance capex from the prior year’s Petro 1 turnaround; future quarters could face higher maintenance spend, pressuring distributable cash flow.

Relevance 7/10Novelty 8/10Timing: Aug. 28 distribution payable, record date Aug. 13, plus Q2 results filed Aug. 4 premarket

Background

This is an SEC 8-K with Exhibit 99.1 reporting Westlake Chemical Partners LP’s Q2 2026 results and related financing/distribution updates.

Company-level read

Ticker impact

$WLKPBullishMedium confidence
Context

WLKP reported Q2 2026 net income of $14.2M, declared a $0.4714/unit distribution, and cited 1.04x trailing-twelve-month coverage.

Expected impact

Moderately positive bias, with upside if coverage remains near 1.0x and ethylene margin assumptions hold; downside risk if distributable cash flow weakens.

Evidence & confidence

The filing provides fresh, decision-relevant datapoints: declared distribution amount and payable date, distributable cash flow and coverage ratio, and a financing maturity extension that reduces near-term refinancing risk.

Market effects

Reinforces the importance of ethylene margin stability and turnaround capex discipline for ethylene-linked MLP cash flows.

Limited direct regional read-through; primarily affects US MLP income sentiment.

Global ethylene demand and margin commentary is referenced, but no new macro shock is quantified.

Counterpoint

Coverage is only 1.04x, so the distribution may be vulnerable if third-party ethylene margins or volumes soften versus the quarter’s assumptions.

Key entities

  • Westlake Chemical Partners LP

    Reports Q2 2026 results, declares $0.4714/unit distribution, and discloses distributable cash flow and coverage.

  • Westlake Chemical OpCo LP

    Ethylene sales agreement with Westlake is cited as supporting stable cash flows.

  • Westlake Corporation

    Amendments to revolving credit agreements and the ethylene sales agreement are referenced.

Related articles

$WLKPMedAI 8/10

Westlake Chemical Partners LP Announces Second Quarter 2026 Results

Westlake Chemical Partners LP (NYSE: WLKP) reported Q2 2026 net income attributable to the partnership of $14.2 million, or $0.40 per limited partner unit, versus $14.6 million in Q2 2025. Operating cash flow was $129.8 million. It declared a $0.4714 per unit distribution, 48th consecutive quarter, with trailing twelve-month coverage of 1.04x. Credit facilities were amended to extend maturities to July 2031.

$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.

$KRPMed

Kimbell Royalty Q2 Earnings Call Highlights

Kimbell Royalty (NYSE:KRP) reported record Q2 adjusted EBITDA of $84.9 million, with cash G&A of $5.9 million ($2.50 per BOE). It declared a $0.47 per common unit cash distribution, up 15% QoQ, and said 47% may be return of capital. The borrowing base rose to $660 million; debt was $478.7 million. Rig activity and production varied by basin.

$KMPRMed

Kemper Q2 Earnings Call Highlights

Kemper (NYSE:KMPR) reported Q2 results and discussed credit-loss allowances tied to surplus notes in its reciprocal exchange, including a $21 million pre-tax charge on $36 million of notes. Holding-company liquidity was $766 million and debt-to-capital rose to 28.3%. Personal auto normalized combined ratio was 102% and commercial 93.7%, with California rate actions and restructuring savings over $80 million run-rate.

$KOPMed

Koppers Q2 Earnings Call Highlights

Koppers (NYSE:KOP) reported Q2 updates on capital spending of about $24M, shareholder returns of $47M, and debt reduction of $22M in the first half. Liquidity was $390M with net debt of $857M and net leverage at 3.5x. The board raised its dividend to $0.09/share. KOP kept 2026 sales guidance at $1.9B-$2.0B but cut adjusted EBITDA to $240M-$250M and EPS to $3.80-$4.20.